<p>A modified vasohibin bearing polyethylene glycol bonded thereto, which satisfies the requirements: (1) the solubility (25°C, pH7.4) is 1mg/mL or above and (2) an anti-angiogenic activity is exerted. The modified vasohibin exhibits a high solubility at a pH around neutrality, and is therefore suitable for use in treating diseases of which the treatment necessitates anti-angiogenic effect.</p>
